In the fight against coronavirus infection, control of the immune response is of decisive importance, an important component of which is the seroprevalence of antibodies to SARS-CoV-2. Immunity to SARS-CoV-2 is formed either naturally or artificially through vaccination. The purpose of this study was to assess the seroprevalence of antibodies to SARS-CoV-2 in the population of Kyrgyzstan. A cross-sectional randomized study of seroprevalence was carried out according to a program developed by Rospotrebnadzor and the St. Petersburg Pasteur Institute, taking into account WHO recommendations. The ethics committees of the Association of Preventive Medicine (Kyrgyzstan) and the St. Petersburg Pasteur Institute (Russia) approved the study. Volunteers (9471) were recruited, representing 0.15% (95% CI 0.14–0.15) of the total population, randomized by age and region. Plasma antibodies (Abs) to the nucleocapsid antigen (Nag) were determined. In vaccinated individuals, Abs to the SARS-CoV-2 receptor-binding domain antigen (RBDag) were determined. Differences were considered statistically significant at p < 0.05. The SARS-CoV-2 Nag Ab seroprevalence was 48.7% (95% CI 47.7–49.7), with a maximum in the 60–69 age group [59.2% (95% CI 56.6–61.7)] and a minimum in group 1–17 years old [32.7% (95 CI: 29.4–36.1)]. The highest proportion of seropositive individuals was in the Naryn region [53.3% (95% CI 49.8–56.8)]. The lowest share was in Osh City [38.1% (95% CI 32.6–43.9)]. The maximum SARS-CoV-2 Nag seropositivity was found in the health-care sector [57.1% (95% CI 55.4–58.8)]; the minimum was seen among artists [38.6% (95% CI 26.0–52.4)]. Asymptomatic SARS-CoV-2 Nag seropositivity was 77.1% (95% CI 75.6–78.5). Vaccination with Sputnik V or Sinopharm produced comparable Ab seroprevalence. SARS-CoV-2 Nag seropositivity in the Kyrgyz population was 48.75% (95% CI 47.7–49.7), with the mass vaccination campaign undoubtedly benefitting the overall situation.

在对抗冠状病毒感染的过程中，控制免疫反应至关重要，其中一个重要组成部分是 SARS-CoV-2 抗体的血清阳性率。对 SARS-CoV-2 的免疫力是通过疫苗接种自然或人工形成的。本研究的目的是评估吉尔吉斯斯坦人群中 SARS-CoV-2 抗体的血清阳性率。根据 Rospotrebnadzor 和圣彼得堡巴斯德研究所制定的一项计划，并考虑到 WHO 的建议，对血清阳性率进行了一项横断面随机研究。预防医学协会（吉尔吉斯斯坦）和圣彼得堡巴斯德研究所（俄罗斯）的伦理委员会批准了这项研究。招募了志愿者 (9471)，占总人口的 0.15% (95% CI 0.14–0.15)，按年龄和地区随机分配。测定了针对核衣壳抗原 (Nag) 的血浆抗体 (Abs)。在接种疫苗的个体中，测定了 SARS-CoV-2 受体结合域抗原 (RBDag) 的抗体。差异被认为具有统计学意义p < 0.05。SARS-CoV-2 Nag Ab 血清阳性率为 48.7% (95% CI 47.7–49.7)，在 60–69 岁年龄组中最高 [59.2% (95% CI 56.6–61.7)]，在第 1– 组中最低17 岁 [32.7% (95 CI: 29.4–36.1)]。血清阳性个体比例最高的是纳伦地区 [53.3% (95% CI 49.8–56.8)]。份额最低的是奥什市 [38.1% (95% CI 32.6–43.9)]。SARS-CoV-2 Nag 血清阳性率最高的是医疗保健部门 [57.1% (95% CI 55.4–58.8)]；最低值出现在艺术家中 [38.6% (95% CI 26.0–52.4)]。无症状 SARS-CoV-2 Nag 血清阳性率为 77.1%（95% CI 75.6–78.5）。用 Sputnik V 或国药公司接种疫苗产生了相当的抗体血清阳性率。吉尔吉斯斯坦人群的 SARS-CoV-2 Nag 血清阳性率为 48.75% (95% CI 47.7–49.7)，